journal article·2023-07

A nanomedicine based on stoichiometric coordination of camptothecin and organoplatinum (II) for synergistic antitumor therapy

Chao Li, Yu Chen, Yong Gao, Xin Wang, Jiaqiang Wang, Peng Zhang, Xiaobo Hu, Lei Li, Weijun Tong, Zhigang Ren, Weitao Yao

Acta Biomaterialia· Volume 164
Publisher page

Abstract

Precise combination therapy, involving multiple chemotherapeutics with pharmacologically synergistic antitumor effects, is a promising approach to address the challenge of monotherapy with insufficient activity towards their targets of interest. We employed Pt←pyridine coordination-driven assembly to construct a stoichiometric coordination complex of camptothecin and organoplatinum (II) (Pt-CPT). The Pt-CPT complex exhibited a remarkable synergistic effect toward several tumor cell lines, which is equal to the optimal synergistic effect of (PEt3)2Pt(OTf)2 (Pt) and CPT mixture at various ratios. An amphiphilic polymer with H2O2-responsiveness and glutathione (GSH)-depleting ability (PO) was used to encapsulate Pt-CPT complex to enable the nanomedicine (Pt-CPT@PO) with prolonged blood circulation and elevated tumor accumulation. The Pt-CPT@PO nanomedicine exhibited remarkable synergistic antitumor efficacy and antimetastatic effect on a mice orthotopic breast tumor model. This work demonstrated the potential of stoichiometric coordination-driven assembly of organic therapeutics with metal-based drugs in developing advanced nanomedicine with optimal synergistic antitumor activity. STATEMENT OF SIGNIFICANCE: In this study, for the first time, we employed Pt←pyridine coordination-driven assembly to construct a stoichiometric coordination complex of camptothecin and organoplatinum (II) (Pt-CPT), with an optimal synergistic effect at various ratios. Then it was encapsulated into an amphiphilic polymer with H2O2-responsiveness and glutathione (GSH)-depleting ability (PO) to enable the nanomedicine (Pt-CPT@PO) with prolonged blood circulation and elevated tumor accumulation. The Pt-CPT@PO nanomedicine exhibited remarkable synergistic antitumor efficacy and antimetastatic effect on a mice orthotopic breast tumor model.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques · Metal complexes synthesis and properties

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (57)

Show source-provided references
1. Topoisomerase I inhibitors: camptothecins and beyond10.1038/nrc1977 ↗
2. Repair of topoisomerase I-mediated DNA damage10.1016/S0079-6603(06)81005-6 ↗
3. Topoisomerase I-mediated DNA damage10.1016/S0065-230X(01)80016-6 ↗
4. Repair of and checkpoint response to topoisomerase I-mediated DNA damage10.1016/j.mrfmmm.2003.08.016 ↗
5. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation10.1038/cr.2017.54 ↗
6. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy10.1073/pnas.1011368107 ↗
7. Beta-cyclodextrin modified Pt(II) metallacycle-based supramolecular hyperbranched polymer assemblies for DOX delivery to liver cancer cells10.1073/pnas.2007798117 ↗
8. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers10.1073/pnas.0711714105 ↗
9. Cisplatin: the first metal based anticancer drug10.1016/j.bioorg.2019.102925 ↗
10. Platinum-based drugs: past, present and future10.1007/s00280-016-2976-z ↗
11. Photo-reduction with NIR light of nucleus-targeting PtIV nanoparticles for combined tumor-targeted chemotherapy and photodynamic immunotherapy10.1002/anie.202201486 ↗
12. The resurgence of platinum-based cancer chemotherapy10.1038/nrc2167 ↗
13. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs10.1021/acs.chemrev.5b00597 ↗
14. The rediscovery of platinum-based cancer therapy10.1038/s41568-020-00308-y ↗
15. A near-infrared-II polymer with tandem fluorophores demonstrates superior biodegradability for simultaneous drug tracking and treatment efficacy feedback10.1021/acsnano.1c00076 ↗
16. Platinum-based drugs for cancer therapy and anti-tumor strategies10.7150/thno.69424 ↗
17. Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance10.1038/s41551-021-00728-7 ↗
18. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer10.1056/NEJMoa003034 ↗
19. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma10.1200/JCO.2008.17.1249 ↗
20. Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated cellular internalization, trafficking, and drug delivery10.1021/ja409686x ↗
21. Cell-penetrating hyperbranched polyprodrug amphiphiles for synergistic reductive milieu-triggered drug release and enhanced magnetic resonance signals10.1021/ja5105848 ↗
22. Tumor-activatable nanoparticles target low-density lipoprotein receptor to enhance drug delivery and antitumor efficacy10.1002/advs.202201614 ↗
23. A synchronized dual drug delivery molecule targeting cancer stem cells in tumor heterogeneity and metastasis10.1016/j.biomaterials.2022.121781 ↗
24. Recapitulating spatiotemporal tumor heterogeneity in vitro through engineered breast cancer microtissues10.1016/j.actbio.2018.04.028 ↗
25. Trackable supramolecular fusion: cage to cage transformation of tetraphenylethylene-based metalloassemblies10.1002/anie.202000078 ↗
26. Self-assembly of porphyrin-containing metalla-assemblies and cancer photodynamic therapy10.1021/acs.inorgchem.9b02775 ↗
27. In situ assembly of platinum(II)-metallopeptide nanostructures disrupts energy homeostasis and cellular metabolism10.1021/jacs.2c03215 ↗
28. Antitumor activity of a unique polymer that incorporates a fluorescent self-assembled metallacycle10.1021/jacs.7b09224 ↗
29. Designed conformation and fluorescence properties of self-assembled phenazine-cored platinum(II) metallacycles10.1021/jacs.9b01368 ↗
30. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile10.1073/pnas.1207670109 ↗
31. understanding the effects of coordination and self-assembly on an emissive phenothiazine10.1021/jacs.9b00363 ↗
32. Light triggered release of a triple action porphyrin-cisplatin conjugate evokes stronger immunogenic cell death for chemotherapy, photodynamic therapy and cancer immunotherapy10.1186/s12951-022-01531-5 ↗
33. A self-assembled Ru-Pt metallacage as a lysosome-targeting photosensitizer for 2-photon photodynamic therapy10.1073/pnas.1912549116 ↗
34. Glutathione-scavenging poly(disulfide amide) nanoparticles for the effective delivery of Pt(IV) prodrugs and reversal of cisplatin resistance10.1021/acs.nanolett.8b01924 ↗
35. Illuminating platinum transportation while maximizing therapeutic efficacy by gold nanoclusters via simultaneous near-infrared-I/II imaging and glutathione scavenging10.1021/acsnano.0c05541 ↗
36. Breaking the intracellular redox balance with diselenium nanoparticles for maximizing chemotherapy efficacy on patient-derived xenograft models10.1021/acsnano.0c06190 ↗
37. Rationally designed polymer conjugate for tumor-specific amplification of oxidative stress and boosting antitumor immunity10.1021/acs.nanolett.9b05265 ↗
38. Self-assembly of cationic, tetranuclear, Pt(II) and Pd(II) macrocyclic squares. X-ray crystal structure of [Pt2+(dppp)(4,4′-bipyridyl)2-OSO2CF3]410.1021/ja00128a015 ↗
39. A discrete organoplatinum(II) metallacage as a multimodality theranostic platform for cancer photochemotherapy10.1038/s41467-018-06574-7 ↗
40. An NIR discrete metallacycle constructed from perylene bisimide and tetraphenylethylene fluorophores for imaging-guided cancer radio-chemotherapy10.1002/adma.202106388 ↗
41. Host-guest complexation-mediated codelivery of anticancer drug and photosensitizer for cancer photochemotherapy10.1073/pnas.1902029116 ↗
42. Dual-emissive platinum(II) metallacage with a sensitive oxygen response for imaging of hypoxia and imaging-guided chemotherapy10.1002/anie.202009442 ↗
43. Theoretical study of cisplatin binding to purine bases: why does cisplatin prefer guanine over adenine?10.1021/ja036960d ↗
44. A systematic strategy of combinational blow for overcoming cascade drug resistance via NIR-light-triggered hyperthermia10.1002/adma.202100599 ↗
45. Polymeric nanoparticles integrated from discrete organoplatinum(II) metallacycle by stepwise post-assembly polymerization for synergistic cancer therapy10.1021/acs.chemmater.0c00615 ↗
46. Design strategies and applications of ROS-responsive phenylborate ester-based nanomedicine10.1021/acsbiomaterials.0c01190 ↗
47. Biodegradable charge-transfer complexes for glutathione depletion induced ferroptosis and NIR-II photoacoustic imaging guided cancer photothermal therapy10.1002/anie.202014852 ↗
48. GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer10.7150/thno.29820 ↗
49. Reactive oxygen species (ROS)-responsive prodrugs, probes, and theranostic prodrugs: applications in the ROS-related diseases10.1021/acs.jmedchem.0c01704 ↗
50. GSSG/GSH ratios in cryopreserved rat and human hepatocytes as a biomarker for drug induced oxidative stress10.1016/j.tiv.2014.04.017 ↗
51. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
52. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?10.1021/acs.bioconjchem.6b00437 ↗
53. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
54. Rational design of cancer nanomedicine: nanoproperty integration and synchronization10.1002/adma.201606628 ↗
55. Targeting metastasis10.1038/nrc.2016.25 ↗
56. Molecular pathogenesis of bone metastases in breast cancer: proven and emerging therapeutic targets10.5306/wjco.v5.i3.335 ↗
57. Breast cancer bone metastases: pathogenesis and therapeutic targets10.1016/j.biocel.2018.01.003 ↗